Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome

Arthritis and Rheumatism

Volumn 56, Issue 11, 2007, Pages 3748-3758

  Han, Bing ^a   Moore, Paul A ^b,c   Wu, Jiangping ^a   Luo, Hongyu ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b GLAXOSMITHKLINE   (United States)

^c Celera Genomics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; COMPLEMENT COMPONENT C3; DECOY RECEPTOR 3; DNA ANTIBODY; DOUBLE STRANDED DNA; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HELA CELL; HEMATURIA; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER; LUPUS LIKE SYNDROME; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SEX DIFFERENCE; SKIN; SYNDROME DELINEATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TRANSGENIC MOUSE; URINALYSIS; WESTERN BLOTTING;

ACTINS; ANIMALS; APOPTOSIS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; LONGEVITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHATIC DISEASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOTYPE; PROMOTER REGIONS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; T-LYMPHOCYTES;

EID: 36048940662     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22978     Document Type: Article

References (36)

1. Santiago-Raber ML, Laporte C, Reininger L, Izui S. Genetic basis of murine lupus. Autoimmun Rev 2004;3:33-9.
2. Salmon M, Gordon C. The role of apoptosis in systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:1177-83.
3. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, et al. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029-34.
4. McNally J, Yoo DH, Drappa J, Chu JL, Yagita H, Friedman SM, et al. Fas ligand expression and function in systemic lupus erythematosus. J Immunol 1997;159:4628-36.
5. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703.
6. Zhang J, Salcedo TW, Wan X, Ullrich S, Hu B, Gregorio T, et al. Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest 2001;107:1459-68.
7. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A 2000;97:1230-5.
8. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002;16:479-92.
9. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 2006;281:13964-71.
10. Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, et al. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 2002;168:4846-53.
11. Wu Y, Han B, Luo H, Roduit R, Salcedo TW, Moore PA, et al. DcR3/TR6 effectively prevents islet primary nonfunction after transplantation. Diabetes 2003;52:2279-86.
12. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 1998;8:21-30.
13. Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, Kwon BS, et al. LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998;102:1142-51.
14. Rooney IA, Butrovich KD, Glass AA, Borboroglu S, Benedict CA, Whitbeck JC, et al. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 2000;275:14307-15.
15. Wan X, Shi G, Semenuk M, Zhang J, Wu J. DcR3/TR6 modulates immune cell interactions. J Cell Biochem 2003;89:603-12.
16. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang Z, et al. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 2003;105:724-32.
17. Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, et al. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol 2000;119:323-7.
18. Luo H, Yu G, Tremblay J, Wu J. EphB6-null mutation results in compromised T cell function. J Clin Invest 2004;114:1762-73.
19. Rathmell JC, Goodnow CC. Effects of the lpr mutation on elimination and inactivation of self-reactive B cells. J Immunol 1994;153:2831-42.
20. Roths JB. Differential expression of murine antoimmunity and lymphoid hyperplasia determined by single genes. In: Kyogoku M, Wigzell H, editors. Horizons in animal models for autoimmune diseases. Tokyo: Academic Press; 1987. p. 21-33.
21. Hayakawa K, Hardy RR, Herzenberg LA, Herzenberg LA. Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. J Exp Med 1985;161:1554-68.
22. Stall AM, Adams S, Herzenberg LA, Kantor AB. Characteristics and development of the murine B-1b (Ly-1 B sister) cell population. Ann N Y Acad Sci 1992;651:33-43.
23. Bohm I. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed Pharmacother 2004;58:338-43.
24. Matsumoto T, Yoshimine T, Shimouchi K, Shiotu H, Kuwabara N, Fukuda Y, et al. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data. Hum Pathol 1992;23:1151-8.
25. Furukawa F, Tanaka H, Sekita K, Nakamura T, Horiguchi Y, Hamashima Y. Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res 1984;276:186-94.
26. Kao AH, Manzi S, Ramsey-Goldman R. Review of ACR hematologic criteria in systemic lupus erythematosus. Lupus 2004;13:865-8.
27. Connolly K, Cho YH, Duan R, Fikes J, Gregorio T, LaFleur DW, et al. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J Pharmacol Exp Ther 2001;298:25-33.
28. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993;178:2231-5.
29. Hacker G, Bauer A, Villunger A. Apoptosis in activated T cells: what are the triggers, and what the signal transducers? Cell Cycle 2006;5:2421-4.
30. Bosque A, Aguilo JI, Alava MA, Paz-Artal E, Naval J, Allende LM, et al. The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling. Blood 2007;109:1627-35.
31. Rao VK, Straus SE. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology 2006;11:15-23.
32. + T cell function in mice lacking the TNF superfamily member LIGHT. J Immunol 2002;168:4832-5.
33. Wang EC, Thern A, Denzel A, Kitson J, Farrow SN, Owen MJ. DR3 regulates negative selection during thymocyte development. Mol Cell Biol 2001;21:3451-61.
34. Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, et al. Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 2005;175:5135-45.
35. Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci U S A 1998;95:14869-74.
36. Gaffney PM, Langefeld CD, Graham RR, Ortmann WA, Williams AH, Rodine PR, et al. Fine-mapping chromosome 20 in 230 systemic lupus erythematosus sib pair and multiplex families: evidence for genetic epistasis with chromosome 16q12. Am J Hum Genet 2006;78:747-58.